

Resource Summary Report

Generated by [nidm-terms](#) on Aug 11, 2026

CD28 Monoclonal Antibody (37.51), Functional Grade, eBioscience

RRID:AB_468923

Type: Antibody

Proper Citation

(Thermo Fisher Scientific Cat# 16-0281-86, RRID:AB_468923)

Antibody Information

URL: http://antibodyregistry.org/AB_468923

Proper Citation: (Thermo Fisher Scientific Cat# 16-0281-86, RRID:AB_468923)

Target Antigen: CD28

Host Organism: syrian hamster

Clonality: monoclonal

Comments: Applications: Flow, Functional
Consolidation on 1/2020: AB_468923, AB_10116059

Antibody Name: CD28 Monoclonal Antibody (37.51), Functional Grade, eBioscience

Description: This monoclonal targets CD28

Target Organism: mouse

Clone ID: Clone 37.51

Antibody ID: AB_468923

Vendor: Thermo Fisher Scientific

Catalog Number: 16-0281-86

Record Creation Time: 20251216T074333+0000

Record Last Update: 20260225T231728+0000

Ratings and Alerts

No rating or validation information has been found for CD28 Monoclonal Antibody (37.51), Functional Grade, eBioscience.

No alerts have been found for CD28 Monoclonal Antibody (37.51), Functional Grade, eBioscience.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 42 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#).

Takehara KK, et al. (2026) Distinct tissue niches contribute to prostate tissue-resident memory CD8+ T cell differentiation and heterogeneity. *Immunity*, 59(5), 1325.

Feng C, et al. (2026) METTL3/CD98-mediated glutamate efflux in CAFs drives CD8+ T cell exhaustion and impedes neoadjuvant immunochemotherapy. *Cell reports*, 45(2), 116933.

Imano N, et al. (2026) Induction of IL-9-producing CD8+ T cells by ascochlorin derivatives. *British journal of pharmacology*, 183(11), 3015.

Niu Y, et al. (2026) Adoptive transfer of TregIL-33 cells ameliorates acute graft-versus-host disease by regulating the HPGD/PGE2 pathway. *International immunopharmacology*, 168(Pt 1), 115700.

Sugiura A, et al. (2026) Tissue and CD4 T cell subset dependence on the amino acid transporter SLC38A1. *Cell metabolism*, 38(4), 712.

Shen J, et al. (2026) Krüppel-like factors 2 and 3 regulate T cell exhaustion by directing T cell residency and migration. *Immunity*, 59(5), 1287.

Xiao Z, et al. (2025) Engineered T cells stimulate dendritic cell recruitment and antigen spreading for potent anti-tumor immunity. *Cell reports. Medicine*, 6(9), 102307.

Wang F, et al. (2025) An age-related decrease in leptin contributes to CD8+ T cell aging in the tumor microenvironment. *Cell reports. Medicine*, 6(9), 102310.

Yuk CM, et al. (2025) Inositol polyphosphate multikinase regulates Th1 and Th17 cell differentiation by controlling Akt-mTOR signaling. *Cell reports*, 44(2), 115281.

Longo J, et al. (2025) Glucose-dependent glycosphingolipid biosynthesis fuels CD8+ T cell function and tumor control. *Cell metabolism*, 37(9), 1890.

Zhang L, et al. (2025) Stress triggers irritable bowel syndrome with diarrhea through a spermidine-mediated decline in type I interferon. *Cell metabolism*, 37(1), 87.

Lin CP, et al. (2024) Multimodal stimulation screens reveal unique and shared genes limiting T cell fitness. *Cancer cell*.

Ding R, et al. (2024) Lactate modulates RNA splicing to promote CTLA-4 expression in tumor-infiltrating regulatory T cells. *Immunity*, 57(3), 528.

Srirat T, et al. (2024) NR4a1/2 deletion promotes accumulation of TCF1+ stem-like precursors of exhausted CD8+ T cells in the tumor microenvironment. *Cell reports*, 43(3), 113898.

Deka A, et al. (2024) Non-canonical NF- κ B signaling limits the tolerogenic β -catenin-Raldh2 axis in gut dendritic cells to exacerbate intestinal pathologies. *The EMBO journal*, 43(18), 3895.

Zou X, et al. (2024) Hypoxia-inducible factor 2 α promotes pathogenic polarization of stem-like Th2 cells via modulation of phospholipid metabolism. *Immunity*, 57(12), 2808.

Istomine R, et al. (2023) The eIF4EBP-eIF4E axis regulates CD4+ T cell differentiation through modulation of T cell activation and metabolism. *iScience*, 26(5), 106683.

Zhang Y, et al. (2023) Dietary fructose-mediated adipocyte metabolism drives antitumor CD8+ T cell responses. *Cell metabolism*, 35(12), 2107.

Chen J, et al. (2023) IL-24 is the key effector of Th9 cell-mediated tumor immunotherapy. *iScience*, 26(9), 107531.

Wan J, et al. (2023) De novo NAD+ synthesis contributes to CD8+ T cell metabolic fitness and antitumor function. *Cell reports*, 42(12), 113518.